For its third fiscal quarter (ending September 30), Avanos Medical Inc (NYSE: AVNS) has reported a -168% decline in E.P.S. from $-0.19 a year ago to $0.13 in the current quarter. For the latest four quarters through September 30, E.P.S. were $0.47 compared to $-0.24 a year ago — a decline of -296%.
Recent Price Action
Avanos Medical Inc (NYSE: AVNS) stock suffered a major decline of -17.9% on 10/30/24. The shares closed at $18.58. Moreover, unusually high trading volume at 164% of normal accompanied the decline. The stock has been exceptionally strong relative to the market over the last nine months but has declined -17.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, AVNS is expected to be a modest Value Builder.
Avanos Medical has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Avanos Medical has a slightly positive Appreciation Score of 68 and a good Power Rating of 82, producing the Highest Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment